Navigation Links
Different subtypes of triple-negative breast cancer respond to different therapies

Vanderbilt-Ingram Cancer Center researchers have identified six subtypes of an aggressive and difficult-to-treat form of breast cancer, called "triple-negative breast cancer (TNBC)."

In the July issue of the Journal of Clinical Investigation, Cancer Center Director Jennifer Pietenpol, Ph.D., and colleagues describe the molecular features of these six distinct subtypes and identify chemotherapies to which the different subtypes respond in cultured cells and animal tumor models. Knowing the specific subtype could help physicians determine which therapies would work best in patients with TNBC and also inform the discovery and development of new drugs to treat this aggressive form of breast cancer, the authors suggest.

Triple negative breast cancers (TNBC) account for 10 percent to 20 percent of all breast cancers and tend to be more aggressive than other types of breast cancer.

"It's a pretty significant health problem from the standpoint that 11 percent of Caucasians, 17 percent of Hispanics, and 25 percent of African-Americans have this type of breast cancer," Pietenpol said.

While some patients with TNBC initially respond well to standard chemotherapy, these tumors are more likely to recur after treatment and have a poorer prognosis (less than 30 percent of women with metastatic TNBC which has spread outside the breast survive 5 years).

The difficulty in treating these tumors stems from what they lack.

The term "triple-negative breast cancer," explained Pietenpol, "is just a definition of what (the cancer) isn't."

TNBC tumors lack the estrogen receptors (ER) and progesterone receptors (PR) that drive the majority (about 60 percent) of breast cancers. They also show no amplification of another receptor, called HER2, which drives about 20 percent to 30 percent of breast cancers.

The absence of these receptors means that the tumors are unlikely to respond to hormone therapies like tamoxifen and to therapies targeted to HER2 like trastuzumab (Herceptin).

Postdoctoral fellows Brian Lehmann, Ph.D., and Joshua Bauer, Ph.D., along with biostatistician Xi (Steven) Chen, Ph.D., identified 587 cases of TNBC among 21 publicly-available breast cancer data sets. They then analyzed the genomic data to uncover unique gene expression profiles (sets of genes that are either turned "up" or "down" in the tumors).

Their analysis revealed six distinct subtypes two "basal-like" types (BL1 and BL2) involving cell cycle and DNA damage response genes; two "mesenchymal" types (M and MSL) driven by genes involved in cell differentiation and growth factor pathways; an "immunomodulatory" (IM) group, driven by immune system genes; and a "luminal" subgroup (LAR) driven by androgen (or "male" sex hormone) signaling.

The researchers also identified cell lines representing each of these subtypes and tested various chemotherapies in development or in clinical investigation in the cell lines. They also implanted these cells into mice to generate animal models of these tumor subtypes.

They found that the basal-like subtypes (BL1 and BL2) responded to cisplatin; the mesenchymal-like subtypes (M and MSL) responded to dasatinib and experimental drug NVP-BEZ235; and the LAR subtypes were sensitive to bicalutamide.

The findings provide a way of distinguishing molecular differences in this diverse group of breast cancers and suggest molecular targets for each subtype that may inform drug discovery and development efforts.

"In our opinion, the big breakthrough is just being able to say 'this isn't one disease,'" said Pietenpol.

Being able to distinguish distinct biological subtypes of TNBC could help guide the design of select clinical trials for subtypes of breast cancer, point toward new biomarkers for patient selection for a given therapy, and identify new targets for drug discovery, she said.

"This really is the first step in translating genomic information into personalizing therapy for women with a very difficult-to-treat breast cancer."


Contact: Dagny Stuart
Vanderbilt University Medical Center

Related medicine news :

1. Reading Arabic or English May Tax Brain Differently
2. Study finds much different work histories for disability rejects, beneficiaries
3. Breast Cancer Recurrence Rates Appear Different When Radiation Used
4. Vitamin D deficiency is associated with different types of obesity in black and white children
5. Signaling pathway reveals mechanism for B cell differentiation in immune response
6. Men and Women May Truly See Things Differently
7. Two Different Heart Drugs May Work Equally Well for High-Risk Patients
8. Many Moms Have Kids With Different Dads, U.S. Study Finds
9. Different genes influence smoking risk during adolescence and adulthood
10. Surviving Melanoma May Take Different Toll on Women, Men
11. Women with eating disorders draw a different picture of themselves than women without
Post Your Comments:
(Date:10/9/2015)... ... October 09, 2015 , ... Head Over Heels Athletic ... elite developmental camp at the Karolyi Ranch in Huntsville, Texas on October 17-21. ... Over Heels girls team head coach and executive director, said. “It's a stepping stone ...
(Date:10/9/2015)... , ... October 09, 2015 , ... On Saturday, September ... World Jump Rope Championship in Madrid, Spain. Representing both the USA and Sweden in ... Double Unders and One-Minute Am Front Crosses, she was awarded 1 Silver and 4 ...
(Date:10/9/2015)... ... October 09, 2015 , ... Confidence Plus Insurance has ... community improvement initiative that involves working with a series of local charities throughout ... Confidence Plus Insurance is the Gleason Park Electric Violin Ensemble (GPEVE). , GPEVE ...
(Date:10/9/2015)... ... October 09, 2015 , ... "As a nurse, I care for male ... "They have to wear large diapers or pads. We came up with this as ... to absorb urine leaking from the tip of the penis. This prevents stains from ...
(Date:10/9/2015)... ... October 09, 2015 , ... MMJ PhytoTech ... with Ed Begley Jr., airing 1st QT 2016 via the Discovery Channel. Dates ... MMJ Phytotech Limited (MMJ) – a global leader in the field of commercializing ...
Breaking Medicine News(10 mins):
... Points Out Fundamental Flaw That May ... Plans to Achieve this Objective, CEDAR KNOLLS, N.J., ... a company specializing in,portable electronic medical records management solutions, ... support for,the adoption of electronic medical records (EMR) to ...
... Webcast -, CHICAGO, Feb. 4 Advanced ... biopharmaceutical company engaged in the,discovery, development and commercialization ... cancer and respiratory diseases, today,announced that its Chairman ... "Antibiotics: Super Drugs Against Super Bugs" panel at ...
... a brain area to later learning deficits , , MONDAY, ... doctors identify children exposed to alcohol during pregnancy but ... with the exposure, a new study suggests. , ... temporal pairing of a conditioned stimulus, such as a ...
... Gap, with the help of,influential fashion stylist Katie Grand, ... a new version of Mulberry,s iconic Roxanne,bag for the ... in,the UK and Paris on December 1, 2007 to ... collection curated by Katie, bringing together a,diverse array of ...
... U.S. Pharmacopeia (USP) is pleased to announce that ... compendia, the United States Pharmacopeia and National Formulary ... edition for 2008, USP 31NF 26, provides specifications ... excipients, dietary supplements, biologics and other therapeutics. , ...
... safe to wait to make a,decision about having prostate ... the doctor appointments and test results? Or will the,additional ... that men can take the time they need to ... Men,s Health Watch., One study evaluated men newly ...
Cached Medicine News:
(Date:10/9/2015)... Lilly and Company (NYSE: LLY ) and Locemia ... Locemia,s intranasal glucagon, a potential treatment for severe hypoglycemia ... which is currently in Phase III clinical trial testing, ... hypoglycemia. --> --> ... formulation that is delivered in an emergency situation using ...
(Date:10/9/2015)... CHAPEL HILL, N.C. , Oct. 9, 2015 ... Pharmaceutical or Medical Device environments, corporate communications is ... external communications, corporations and professionals must continuously adjust ... the effectiveness of these adjustments is difficult, but ... to today,s communication options. ...
(Date:10/9/2015)... Regulatory affairs groups within medical device organizations face ... --> These specialized groups are charged with ensuring that ... pertaining to the development and marketing of medical device products. ... on their own internal effectiveness and efficiencies to remain productive ... --> --> Optimal resourcing and staffing ...
Breaking Medicine Technology:
... DIEGO , May 6 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... financial results for the first quarter ended March 31, 2010 on ... followed by a live webcast and conference call at 5:00 p.m. Eastern ... Orexigen management will ...
... , May 6 DUSA Pharmaceuticals, Inc. ( DUSA ) announces that its corporate ... 6:30 a.m. to be followed by a conference call at 8:30 a.m. , ... - 8:30 a.m. E.T. , , , ... , , 800-647-4314 , ...
Cached Medicine Technology:
Microwell EIA for the detection of EPO (Erythropoietin)...
Microwell EIA for detection of Calcitonin...
... PREMIUM SURGICLIP II™ single use ... Super Interlock™ clips., ,The ... applier has application in many ... occlude vessels and other tubular ...
... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
Medicine Products: